Karen Krok, MD
Gastroenterology · Hershey, PANPI 1003983404
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,840 of the $54,292 with a category attached, or 77.1%. Gilead accounts for 65.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $25,238 and has fallen 87.5% since, to $3,161 in 2025. Among gastroenterology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $565.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$36K
- AbbVie$10K
- Intercept Pharmaceuticals, Inc.$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Merck$1K
- Ipsen Biopharmaceuticals, Inc$405
- plus $592 from 8 others
Across 253 payments — averaging $2258.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$293K
- Gilead$96K
- Boehringer Ingelheim International GmbH$52K
- Intercept Pharma Europe Ltd.$40K
- Ipsen Pharma SAS$25K
- Ipsen Bioscience Inc.$21K
- plus $43K from 3 others
What the payments were for
- Consulting fees$4,3358%
- Speaking & faculty fees$41,84077%
- Travel & lodging$5,83811%
- Food & beverage$2,2334%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 50 | $35,503 |
| AbbVie | 17 | $10,416 |
| Intercept Pharmaceuticals, Inc. | 4 | $4,792 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $1,363 |
| Merck | 1 | $1,220 |
| Ipsen Biopharmaceuticals, Inc | 5 | $405 |
| Madrigal Pharmaceuticals | 2 | $251 |
| Mallinckrodt Hospital Products Inc. | 2 | $174 |
| Novo Nordisk | 3 | $72 |
| Braintree Laboratories, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| Shionogi Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,292 in reported general payments places this provider in the 90th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 84 | $263,007 |
| Ursodiol | 135 | $26,336 |
| VemlidyTenofovir Alafenamide | 13 | $15,960 |
| EliquisApixaban | 15 | $8,596 |
| LinzessLinaclotide | 13 | $7,230 |
| Tacrolimus | 82 | $6,121 |
| Mycophenolate Mofetil | 24 | $2,575 |
| Mycophenolic AcidMycophenolate Sodium | 31 | $1,781 |
| Lactulose | 17 | $1,326 |
| Spironolactone | 80 | $635 |
| Azathioprine | 31 | $616 |
| Omeprazole | 65 | $532 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 27 | $524 |
| Prednisone | 77 | $441 |
| Carvedilol | 74 | $386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,363 | $263,00784 claims |
| GileadVemlidy | $35,503 | $15,96013 claims |
| AbbVieLinzess | $10,416 | $7,23013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Hershey
- Kofi ClarkeHershey$426K
- Andrew TinsleyHershey$322K
- Emmanuelle WilliamsHershey$212K
- Quaadir Otto-SmallwoodHershey$63K
- Miguel RegueiroPittsburgh$1.5M
- Adam PeytonAllentown$985K
- Shahin RahimianWaynesboro$592K
- Sandra El-HachemPittsburgh$472K
- Harshit KharaDanville$438K
- Michael KochmanPhiladelphia$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.